Press Releases
June 13, 2018
SBP Doses First Patients in 2nd Clinical Study of SBP-101
SUN BIOPHARMA, INC. DOSES FIRST PATIENTS IN SECOND CLINICAL STUDY OF SBP-101 FOR PANCREATIC DUCTAL ADENOCARCINOMA
- After Successful Completion of the Phase 1 Dose Escalation/Safety Study of SBP-101, New Combination Study Opens for Previously Untreated Metastatic Pancreatic Cancer Patients
- SBP-101 is a Proprietary Polyamine Analogue Targeted Specifically for Pancreatic Diseases
- SBP-101 was Invented by Emeritus Professor Raymond Bergeron at the University of Florida in Gainesville, Florida, USA with World-Wide Exclusive Rights Licensed to Sun BioPharma, Inc.
May 14, 2018
SBP Provides Business Update and Files Report for Q1 2018
April 16, 2018
SBP Announces Appointment of Susan Horvath as VP of Finance and CFO
March 21, 2018
SBP Provides Business Update & Files Annual Report for 2017
February 27, 2018
SBP Files U.S. Patent Protecting Manufacturing Process for SBP-101
January 29, 2018
SBP Announces Initiation of First-line Combination Study of SBP-101
November 14, 2017
SBP Files Form 10-Q for 3rd Quarter 2017 & Provides Business Update
October 4, 2017
SBP Achieves Significant Milestone with Successful Completion of Patient Enrollment in Phase 1a Dose Escalation Safety Study
August 10, 2017
SBP Files Form 10-Q for Second Quarter 2017 and Provides Clinical Update
Events & Presentations